Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 3/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467929 | 0.87 | PDGFRA (0.69) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL4482576 | 0.87 | PDGFRA (0.69) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL22505699 | 0.86 | PDGFRA (0.60) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL4480462 | 0.84 | PDGFRB (0.64) | PDGFRBPDGFRAKDRAXLFGFR2 | |
| SCHEMBL19957167 | 0.83 | PDGFRA (0.51) | PDGFRBPDGFRAKDRCSF1RRET | |
| SCHEMBL15960723 | 0.82 | PDGFRA (0.57) | PDGFRBPDGFRAKDRRETKIT | |
| SCHEMBL28125152 | 0.80 | PDGFRA (0.53) | PDGFRBPDGFRAKDRRETKIT | |
| SCHEMBL19957069 | 0.80 | PDGFRA (0.53) | PDGFRBPDGFRAKDRCSF1RAXL | |
| SCHEMBL15537359 | 0.80 | KDR (0.55) | PDGFRBPDGFRAKDRFGFR2 | |
| SCHEMBL21253618 | 0.80 | PDGFRA (0.52) | PDGFRBPDGFRAKDRRETKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | PDGFRB 98/4885PDGFRA 127/4885KDR 150/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | PDGFRB 98/4885PDGFRA 127/4885KDR 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.